Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 0,95 € (-31,16%). La mediana è 0,95 € (-31,16%).
| Acquista |
7 |
| Mantieni |
1 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Myomo raises 2026 revenue guidance after Q2 revenue grows 21%
Myomo reported Q2 revenue of $11.7 million, up 21% year over year, driven by a 19% increase in recognized MyoPro units to 211 and a record 255 orders. Recurring referral sources now account for 53% of quarterly revenue (vs. 26% a year earlier) as the company expands its referral network above 300 sites. Gross margin improved to 72.1% and operating loss narrowed to $2.3 million; adjusted EBITDA loss fell to $800,000. Management raised full-year 2026 revenue guidance to $45 million–$47 million, expects Q3 revenue of $11.5 million–$12 million, and forecasts second-half cash burn below $2 million. » Altro su finance.yahoo.com
Myomo beats Q2 expectations and raises revenue guidance
Myomo reported a 21% rise in Q2 revenue to $11.7 million, a reduced net loss of $0.09 per share and a markedly improved gross margin of 72.1%. The quarter was supported by a record order intake of 255 MyoPro units and 211 devices delivered. The company raised its 2026 revenue guidance to $45–47 million and signaled progress on operating leverage. The stock rose modestly in after-hours trading following the results. » Altro su de.investing.com
Myomo beats Q1 forecasts, stock falls after-hours
Myomo reported better-than-expected Q1 results: EPS -$0.07 (expected -$0.12) and revenue $10.1 million (expected $9.24 million). Revenue rose 3% year-on-year, gross margin improved to 68.2%, and the company shipped 172 MyoPro units. For Q2 Myomo forecasts revenue between $10.3 million and $10.8 million; nevertheless the stock fell after-hours, initially by 2.98% and then declined further. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 10,26 Mln | 25,23% |
| Utile lordo | 7,4 Mln | 44,07% |
| Utile netto | -3,52 Mln | 10,34% |
| EBITDA | -3,03 Mln | 12,03% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 53,37 Mln € |
Numero di azioni | 38,64 Mln |
Massimo/minimo a 52 settimane | 1,63 € - 0,52 € |
| Dividendi | No |
Beta | 1,44 |
Rapporto P/E | -4,70 |
Rapporto PEG | 0,11 |
Rapporto P/B | 11,72 |
Rapporto P/S | 1,43 |
Profilo aziendale
Myomo, Inc. ist ein Unternehmen für tragbare medizinische Robotik und entwirft, entwickelt und produziert myoelektrische Orthesen für Menschen mit neuromuskulären Störungen in den Vereinigten Staaten. Das Unternehmen bietet MyoPro an, eine myoelektrisch gesteuerte Orthese für die oberen Gliedmaßen, die zur Unterstützung des schwachen oder gelähmten Arms eines Patienten verwendet wird, um funktionelle Aktivitäten des täglichen Lebens zu ermöglichen und zu verbessern. Die Produkte des Unternehmens wurden entwickelt, um die Funktion von Erwachsenen und Jugendlichen mit neuromuskulären Erkrankungen aufgrund von Verletzungen des Plexus brachialis, Schlaganfall, Schädel-Hirn-Trauma, Rückenmarksverletzungen und anderen neurologischen Erkrankungen zu verbessern. Das Unternehmen verkauft seine Produkte an Anbieter von Orthesen und Prothesen, die Veterans Health Administration und Rehabilitationskliniken sowie über Vertriebshändler. Myomo, Inc. wurde im Jahr 2004 gegründet und hat seinen Hauptsitz in Boston, Massachusetts.
| Nome | MYOMO INC. NEW DL-,0001 |
| CEO | Paul R. Gudonis |
| Sede centrale | Burlington,
ma Stati Uniti |
| Sito web | |
| Settore | Industria |
| Industria | Servizi e forniture commerciali |
| Quotazione in borsa | 12/06/2017 |
| Dipendenti | 195 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
AMEX | MYO |
Frankfurt | 0M61.F |
Düsseldorf | 0M61.DU |
Scopri gli asset
Gli azionisti di MYOMO INC. NEW DL-,0001 investono anche nei seguenti asset


